Prothena Corp. (NASDAQ: PRTA) reported Q1 EPS of ($1.12), $0.11 better than the analyst estimate of ($1.23). Revenue for the quarter came in at $2.83 million versus the consensus estimate of $9.54 million.

2025 Financial Guidance

The Company continues to expect the full year 2025 net cash used in operating and investing activities to be between $168 to $175 million and expects to end the year with approximately $301 million (midpoint) in cash, cash equivalents and restricted cash. The estimated full year 2025 net cash used in operating and investing activities is primarily driven by an estimated net loss of $197 to $205 million, which includes an estimated $41 million of non-cash share-based compensation expense.

For earnings history and earnings-related data on Prothena Corp. (PRTA) click here.